AbbVie Hits a New 52-Week High at $265.97, Clearing Its July Peak

As seen on the 24/7 Wall St. homepage on August 19, 2026.

ABBV AbbVie
New 52-week high $265.97 +1.0% vs prior high · 2026-07-29
$271$233$196

AbbVie touched a new 52-week high at $265.97, clearing its July 29 peak. The $470 billion pharma has left its spring range near $200 behind.

Continue ReadingShow less

AbbVie set a new 52-week high of $265.97 on August 19, clearing the July 29 peak and leaving the spring range behind.

Buyers who wait for confirmation are already paying up: the old sellers from that range have been absorbed.

Momentum carried the stock into the new high without a meaningful pullback in the final leg.

Keep an eye on whether $265.97 holds as support on the first test.

Sources

Mentioned: ABBV

Related Market Updates

ABBV AbbVie
New 52-week high $266.28 +0.1% vs prior high · 2026-08-19
$272$232$192

AbbVie cleared its August record with a fresh 52-week high at $266.28, 0.12% above the prior peak, on the same day it announced FDA approval of JUVMO. A $470.9 billion pharma making new highs is a momentum signal income investors rarely get.

Read more
HOUSE TRADE DISCLOSURE Pete Sessions
  • ABBV AbbVie Inc. Common Stock (ABBV)Sell$15K – $50K
  • GOOGL ET IRA Alphabet Inc. - Class A Common Stock (GOOGL)Sell$15K – $50K
Disclosed 4 days after the earliest trade

Sessions dumped a big pharma name and Alphabet on the same day, then filed within four days, an unusually fast turnaround that pins down the timing. Paired healthcare and megacap tech selling from a sitting House member is a signal to catch before the next leg of either trade.

Read more
52-week highs
6 stocks hit new 52-week highs this week
  • SSentinelOne$20.94+6.1%
  • KOCoca-Cola$91.1+2.3%
  • EXPEExpedia$321.63+1.3%
  • ABNBAirbnb$187.3+1.2%
  • ABBVAbbVie$264.96+1.0%
  • PFEPfizer$28.07+0.6%

Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.

Read more